Marcus Schindler | BiotechTV

top of page

At Nucleate UK's The Forum in London, former Novo Nordisk CSO Marcus Schindler reflects on the success of the GLPs and shares advice for biotech entrepreneurs in Europe

He believes that GLPs will always be the backbone of weight loss therapies and points out that they are the only weight loss medicines that have shown a cardiovascular benefit. Plus, why he thinks entrepreneurs in Europe should take a nod from other areas and be more nimble and take more risks in the future.

Bright Minds

20 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

At Nucleate UK's The Forum in London, former Novo Nordisk CSO Marcus Schindler reflects on the success of the GLPs and shares advice for biotech entrepreneurs in Europe

Follow BiotechTV

Sponsors

Sponsor Spotlight